Atrial Natriuretic Peptide (ANP), rat: Molecular Mechanisms and Research Applications

Executive Summary: Atrial Natriuretic Peptide (ANP), rat, is a 28-amino acid peptide hormone with vasodilatory and natriuretic actions, crucial for cardiovascular, renal, and metabolic research (APExBIO A1009 product page). It is synthesized by atrial myocytes in response to physiological stimuli like atrial distension and angiotensin II. ANP regulates body water, sodium, potassium, and adipose tissue, directly impacting blood pressure homeostasis. The APExBIO reagent ensures ≥95.92% purity by HPLC, is soluble in DMSO and water, and enables reproducible, high-precision experiments. Its use extends across blood pressure, natriuresis, and adipose metabolism studies, with translational implications for cardiovascular disease models (see prior review).

Biological Rationale

Atrial Natriuretic Peptide (ANP), rat, is an endogenous peptide hormone secreted by atrial myocytes in response to increased blood volume, atrial stretch, angiotensin II, endothelin, and sympathetic nervous system activation (APExBIO). Its molecular formula is C₄₉H₈₄N₂₀O₁₅S with a molecular weight of 1225.38 Da. ANP acts primarily as a vasodilator and natriuretic agent, facilitating the excretion of sodium (natriuresis) and water, which decreases blood volume and systemic blood pressure. This peptide is essential for maintaining the homeostatic balance of body fluids, electrolytes, and adipose tissue metabolism. Its biological actions are mediated through natriuretic peptide receptors (NPR-A, NPR-B, and NPR-C) present on vascular smooth muscle, renal, and adipose tissues. ANP is stored and released in response to acute hemodynamic changes and serves as a counter-regulatory hormone to the renin–angiotensin–aldosterone system (RAAS).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

ANP binds primarily to the natriuretic peptide receptor-A (NPR-A), a guanylyl cyclase-linked receptor. Upon binding, NPR-A catalyzes the conversion of GTP to cyclic GMP (cGMP), triggering downstream signaling pathways that induce vasodilation and promote natriuresis (Big Endothelin-1 dossier). Elevated cGMP levels in vascular smooth muscle cells lead to relaxation and reduced peripheral vascular resistance. In the kidney, ANP increases glomerular filtration rate (GFR), inhibits sodium reabsorption in the distal nephron, and suppresses renin, aldosterone, and antidiuretic hormone secretion. In adipose tissue, ANP stimulates lipolysis via cGMP-dependent protein kinase pathways, with potential cross-talk to adiponectin regulation (Zhang et al., 2022). The peptide sequence for ANP (rat) is H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH, which is essential for receptor specificity and functional activity.

Evidence & Benchmarks

• APExBIO’s ANP (A1009) is confirmed ≥95.92% pure by HPLC and mass spectrometry, ensuring experimental reproducibility (APExBIO).
• ANP infusion in rat models induces natriuresis and diuresis, reducing blood pressure in a dose-dependent manner (Zhang et al., 2022, DOI).
• ANP is soluble at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water, but insoluble in ethanol, enabling flexible protocol integration (APExBIO).
• In cardiovascular disease models, ANP administration attenuates hypertension and cardiac hypertrophy by antagonizing the RAAS (see mechanistic insights).
• ANP’s actions on adipose tissue metabolism are mechanistically distinct from adiponectin but may interact via cGMP-linked pathways (Zhang et al., 2022, DOI).

Applications, Limits & Misconceptions

ANP, rat, is widely used in studies of blood pressure regulation, renal physiology, and adipose tissue metabolism. It serves as a benchmark for evaluating natriuretic and vasodilatory responses in cardiovascular research. The product is integral to disease modeling in hypertension, heart failure, and obesity-related metabolic syndromes. APExBIO’s formulation supports both in vitro and in vivo experimental designs. This article extends prior work by providing new guidance on experimental integration and clarifying solubility and stability parameters not covered in previous workflow articles.

Common Pitfalls or Misconceptions

• ANP is not effective as a direct anti-inflammatory agent in neurocognitive models; its primary action is on natriuresis and vasodilation.
• Peptide must be freshly dissolved; long-term storage of solution leads to loss of activity.
• ANP is insoluble in ethanol; attempts to prepare solutions in ethanol will fail.
• ANP (rat) cannot be directly extrapolated to human clinical dosing due to species-specific receptor affinities.
• ANP does not substitute for adiponectin in neuroimmune modulation, as shown by comparative studies (Zhang et al., 2022).

Workflow Integration & Parameters

For experimental use, ANP should be reconstituted at ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water. Solutions should be prepared immediately before use and not stored long-term. The lyophilized peptide must be stored at -20°C for stability. Typical in vivo rat studies administer ANP via intravenous or intraperitoneal injection at 1–10 μg/kg, with dosing regimens tailored to study objectives and animal weight (product page). In vitro applications often use 10–100 nM concentrations, depending on cell type and endpoint. Researchers are advised to consult this workflow optimization guide for troubleshooting and comparative strategies, as this piece updates integration practices with new solubility and purity data.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat, from APExBIO (A1009) offers a robust tool for dissecting mechanisms of blood pressure regulation, natriuresis, and metabolic homeostasis in preclinical research. Its high purity, validated solubility, and batch consistency support rigorous cardiovascular and renal physiology investigations. Future directions include deeper exploration of ANP’s crosstalk with adipokines and translational modeling in complex disease systems. For the most up-to-date protocols, researchers should reference the Atrial Natriuretic Peptide (ANP), rat product page and consult recent mechanistic reviews (see neurocardiometabolic update).